
Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

* Surname:

* Given Name:

* OHIN: * Chart Number:

* Postal Code:

* Height (cm): * Weight (kg):

* BSA (m²): * Gender: ☐ Male ☐ Female ☐ Other

* Date of Birth:
Day Month Year

* Site:

* Attending Physician (MRP- Most Responsible Physician):

Requested Prior Approval ☐ Yes * Patient on Clinical Trial ☐ Yes ☐ No

Other (specify):

Specify Arm:
☐ Standard of care arm ☐ Experimental arm
☐ Blinded / Unknown

Request prior approval for enrolment

* Justification for Funding

.....

2. Eligibility Criteria

The patient meets all of the following criteria:

- a. The patient has newly diagnosed multiple myeloma and is eligible for autologous stem cell transplantation^a ☐ Yes

- b. Bortezomib is used as a component of induction therapy pre-autologous stem cell transplantation (ASCT)^b

3. Funded Dose

Bortezomib must be used as part of combination therapy^b. Funded doses may include either of the following:

- ☐ Bortezomib 1.3mg/m² IV or sc Days 1, 4, 8, and 11 of each cycle for 4 cycles^c (1 cycle = 21 days), or
- ☐ Bortezomib 1.5mg/m² IV or sc weekly on Days 1, 8, 15, and 22 of each cycle for 4 cycles^c (1 cycle = 28 days)

4. Notes

- a. The patient must not have received prior therapy (e.g., dexamethasone, chemotherapy, or immunomodulator-based therapy) for multiple myeloma.
- b. Bortezomib-based combination therapy can include the addition of dexamethasone, alkylator or anthracycline chemotherapy, or immunomodulator-based therapy to the bortezomib backbone.
- c. For additional doses, prior authorization is required.

5. Supporting Documents

To ensure reimbursement of your claim, both the completed enrolment form and a copy of the required documentation (where applicable) must be submitted through CCO e-Claims.

Signature of Attending Physician (MRP- Most Responsible Physician):

.....
Day Month Year